Skip to content

Microdosing: all studies

Page 17 of 56: studies 161 to 170 of 555, newest first. Back to the microdosing overview

Research

Microdosing: Old Wine in a New Bottle? Current State of Affairs and Future Avenues.

International Journal of Sports Physiology and Performance October 6, 2022 José Afonso, F. Nakamura, Ivan Baptista et al.

PURPOSE Microdosing of exercise aims to deliver smaller daily training doses but at a higher weekly frequency, adding up to a similar weekly volume as in nonmicrodosed training. This commentary critically discusses this concept, which appears to be a rebranding of the "old" distributed practice of motor learning. DEVELOPMENT We propose that microdosing should relate to the minimal dose that...

Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis

Addiction Science & Clinical Practice October 4, 2022 Adams K. K., Miech E. J., Sobieraj D. M.

Abstract Background Novel buprenorphine dosing strategies have emerged with an aim to transition patients from opioid agonists to buprenorphine without prerequisite opioid withdrawal. We applied a configurational approach to a subset of data from our earlier systematic review to answer the following question: when patients received a buprenorphine initiation strategy aimed to eliminate...

Microdosing with classical psychedelics: Research trajectories and practical considerations

Transcultural Psychiatry October 1, 2022 Alice Wong, Amir Raz 10 citations

Microdosing—the intermittent ingestion of minute, sub-hallucinogenic amounts of psychedelic substances, repeatedly and over time—has become a widespread, albeit largely understudied, phenomenon. Regulations around using psychedelics at any dose—micro, mini, macro, or mega—pose all sorts of difficulties for those who wish to systematically study the effects of Schedule I drugs, especially in the...

Microdosing psilocybin for chronic pain: a case series

Pain September 5, 2022 Matthew Lyes, Joel Castellanos, Timothy Furnish et al. 55 citations

Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of...

Natural language signatures of psilocybin microdosing.

Psychopharmacology September 1, 2022 Camila Sanz, Federico Cavanna, Stephanie Müller et al. 1 citation

Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, mental function, and creativity. Recent studies have found mixed results concerning the effects of low doses of psychedelics ("microdosing") on these domains. However, microdosing is generally investigated using instruments designed to assess larger doses of...

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

Transcultural Psychiatry August 29, 2022 Ayse Ceren Kaypak, Amir Raz 17 citations

To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic intervention. This variation in...

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Translational Psychiatry August 2, 2022 Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente et al. 130 citations

Abstract The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation...

Turn On, Tune In, Drop Out? A Typology of Psychedelic Microdosing as Technologies of the Self

Journal of Cultural Analysis and Social Change July 31, 2022 Kamile Grusauskaite, Koen van Eijck 3 citations

Psychedelic microdosing, or taking small doses of psychedelic substances that do not induce intoxication or altered states but rather subtle outcomes such as increased focus, has quickly become a mass media phenomenon. Many claim microdosing has become the new secret to enhancement in work contexts. Drawing from literature on psychedelic microdosing, technologies of the self, self-identity and...

DOI: 10.20897/jcasc/12255 (opens in new tab) Full text (opens in new tab) Typology Perspective graphical Human enhancement Identity music +2

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Scientific Reports July 28, 2022 Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al. 2 citations

Authors and Affiliations Department of Psychology, University of British Columbia, Kelowna, BC, Canada Joseph M. Rootman & Zach Walsh Quantified Citizen Technologies Inc., Vancouver, BC, Canada Maggie Kiraga, Kalin Harvey & Eesmyal Santos-Brault Department of Family Medicine, University of British Columbia, Vancouver, BC, Canada Pamela Kryskow Fungi Perfecti, LLC, MycoMedica Life Sciences,...

DOI: 10.1038/s41598-022-17428-0 (opens in new tab) Full text (opens in new tab) Microdosing psilocybin Small doses psilocybin Low dose psilocybin Mental health improvement +5

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Scientific Reports June 30, 2022 Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al. 53 citations

Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further...